Search

Displaying results 6241 - 6250 of 10000 in total
  1. Drug

    Pagoclone

    go.drugbank.com/drugs/DB04903
    Investigational

    It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures … Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone.

  2. Drug

    Tizaterkib

    go.drugbank.com/drugs/DB21296
    Investigational

    Tizaterkib has a monoisotopic molecular weight of 494.2 Da. … Tizaterkib is under investigation in clinical trial NCT04305249 (Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological

  3. Drug

    Fluoride ion

    go.drugbank.com/drugs/DB11257
    ApprovedInvestigational

    Having a chemical formula of F−, fluoride ion is the simplest inorganic, monatomic anion of fluorine with basic properties. It is considered a trace element. … It also plays an essential physiological role, such as enhancing the resistance profile and strength of the surface tooth enamel.

    Mixtures: ADDAMEL N, ZYMAFLUOR D 500Synonyms: Fluoride ion
  4. Drug

    Halofuginone

    go.drugbank.com/drugs/DB04866
    InvestigationalVet approved

    Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000. … Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression.

  5. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection. … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid

  6. Drug

    Pomisartan

    go.drugbank.com/drugs/DB20188
    Experimental

    Pomisartan has a monoisotopic molecular weight of 490.24 Da. … The usage of the INN stem '-sartan' in the name indicates that Pomisartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

  7. Drug

    Milfasartan

    go.drugbank.com/drugs/DB20355
    Experimental

    Milfasartan has a monoisotopic molecular weight of 554.21 Da. … The usage of the INN stem '-sartan' in the name indicates that Milfasartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

  8. Drug

    Gemilukast

    go.drugbank.com/drugs/DB19882
    Investigational

    Gemilukast is under investigation in clinical trial NCT01536041 (A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients). Gemilukast has a monoisotopic molecular weight of 601.26 Da. … The usage of the INN stem '-lukast' in the name indicates that Gemilukast is a leukotriene receptor antagonist.

  9. Drug

    Human papillomavirus type 6 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10299
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces

  10. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. … TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders.